CONMED Pretax Profit Margin vs Gross Profit Margin Analysis
CNMD Stock | USD 74.91 3.20 4.46% |
CONMED financial indicator trend analysis is way more than just evaluating CONMED prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CONMED is a good investment. Please check the relationship between CONMED Pretax Profit Margin and its Gross Profit Margin accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.
Pretax Profit Margin vs Gross Profit Margin
Pretax Profit Margin vs Gross Profit Margin Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CONMED Pretax Profit Margin account and Gross Profit Margin. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between CONMED's Pretax Profit Margin and Gross Profit Margin is -0.27. Overlapping area represents the amount of variation of Pretax Profit Margin that can explain the historical movement of Gross Profit Margin in the same time period over historical financial statements of CONMED, assuming nothing else is changed. The correlation between historical values of CONMED's Pretax Profit Margin and Gross Profit Margin is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pretax Profit Margin of CONMED are associated (or correlated) with its Gross Profit Margin. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit Margin has no effect on the direction of Pretax Profit Margin i.e., CONMED's Pretax Profit Margin and Gross Profit Margin go up and down completely randomly.
Correlation Coefficient | -0.27 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Pretax Profit Margin
Gross Profit Margin
Most indicators from CONMED's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CONMED current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.At present, CONMED's Enterprise Value is projected to increase significantly based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 568.0M | 571.2M | 643.1M | 675.2M | Total Revenue | 1.0B | 1.0B | 1.2B | 1.3B |
CONMED fundamental ratios Correlations
Click cells to compare fundamentals
CONMED Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CONMED fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.8B | 1.8B | 1.8B | 2.3B | 2.3B | 2.4B | |
Short Long Term Debt Total | 768.8M | 775.9M | 684.7M | 1.1B | 991.3M | 1.0B | |
Other Current Liab | 64.8M | 111.0M | 126.2M | 153.4M | 222.5M | 233.6M | |
Total Current Liabilities | 188.1M | 190.2M | 196.6M | 296.6M | 310.7M | 326.3M | |
Total Stockholder Equity | 710.5M | 709.0M | 785.4M | 745.5M | 834.2M | 428.2M | |
Property Plant And Equipment Net | 118.9M | 111.4M | 108.9M | 115.6M | 137.3M | 92.9M | |
Net Debt | 743.0M | 748.5M | 663.8M | 1.0B | 967.0M | 1.0B | |
Retained Earnings | 470.8M | 457.4M | 496.6M | 412.6M | 452.5M | 246.1M | |
Cash | 25.9M | 27.4M | 20.8M | 28.9M | 24.3M | 17.2M | |
Non Current Assets Total | 1.4B | 1.3B | 1.3B | 1.7B | 1.7B | 1.8B | |
Non Currrent Assets Other | 102.3M | 96.8M | 98.8M | 93.9M | 79.5M | 83.5M | |
Cash And Short Term Investments | 25.9M | 27.4M | 20.8M | 28.9M | 24.3M | 17.5M | |
Net Receivables | 189.1M | 177.2M | 183.9M | 191.3M | 242.3M | 254.4M | |
Common Stock Shares Outstanding | 29.5M | 29.5M | 32.2M | 30.0M | 31.5M | 25.9M | |
Liabilities And Stockholders Equity | 1.8B | 1.8B | 1.8B | 2.3B | 2.3B | 2.4B | |
Non Current Liabilities Total | 876.5M | 852.4M | 783.9M | 1.3B | 1.2B | 1.2B | |
Inventory | 164.6M | 194.9M | 231.6M | 332.3M | 318.3M | 334.2M | |
Other Current Assets | 17.8M | 17.3M | 23.8M | 28.6M | 30.8M | 32.3M | |
Other Stockholder Equity | 298.6M | 315.0M | 342.7M | 390.5M | 431.5M | 453.1M | |
Total Liab | 1.1B | 1.0B | 980.6M | 1.6B | 1.5B | 1.5B | |
Property Plant And Equipment Gross | 118.9M | 111.4M | 372.6M | 393.1M | 412.9M | 433.5M | |
Total Current Assets | 397.4M | 416.7M | 460.1M | 581.2M | 615.6M | 646.4M | |
Accumulated Other Comprehensive Income | (59.3M) | (63.7M) | (54.2M) | (57.9M) | (50.2M) | (47.7M) | |
Short Term Debt | 13.6M | 25.9M | 12.2M | 69.7M | 16.4M | 16.8M | |
Intangible Assets | 532.8M | 501.5M | 471.0M | 681.8M | 649.5M | 331.7M | |
Accounts Payable | 56.0M | 53.3M | 58.2M | 73.4M | 88.2M | 92.6M | |
Good Will | 618.0M | 618.4M | 617.5M | 815.4M | 806.8M | 430.8M | |
Other Liab | 104.2M | 102.5M | 98.8M | 258.7M | 297.5M | 312.3M | |
Other Assets | 84.9M | 103.6M | 89.0M | 85.8M | 98.7M | 103.6M | |
Long Term Debt | 755.2M | 734.8M | 672.4M | 985.1M | 973.1M | 1.0B | |
Treasury Stock | (80.7M) | (67.6M) | (54.1M) | (22.8M) | (20.5M) | (21.5M) | |
Property Plant Equipment | 118.9M | 111.4M | 108.9M | 115.6M | 133.0M | 129.3M | |
Current Deferred Revenue | 53.7M | 50.2M | 60.5M | 9.7M | (8.2M) | (7.8M) | |
Net Tangible Assets | (440.4M) | (410.9M) | (340.8M) | (751.7M) | (676.5M) | (642.7M) | |
Retained Earnings Total Equity | 470.8M | 457.4M | 496.6M | 412.6M | 474.5M | 467.3M | |
Long Term Debt Total | 755.2M | 735.2M | 672.4M | 985.1M | 1.1B | 1.2B | |
Capital Surpluse | 379.3M | 382.6M | 396.8M | 413.2M | 475.2M | 384.5M | |
Deferred Long Term Liab | 74.5M | 57.9M | 68.5M | 66.7M | 60.1M | 72.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CONMED is a strong investment it is important to analyze CONMED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CONMED's future performance. For an informed investment choice regarding CONMED Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.14 | Dividend Share 0.8 | Earnings Share 4.22 | Revenue Per Share 41.821 | Quarterly Revenue Growth 0.04 |
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.